Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient, they are approved for different purposes. Ozempic is primarily used for managing type 2 diabetes, whereas Wegovy is specifically approved for weight loss.

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, potentially leading to serious health complications over time. Experts call for more research and a cautious approach to using these drugs,

Weight-loss drugs are transforming both health care and Wall Street, with leading manufacturers like Eli Lilly & Co. (LLY) and Novo Nordisk A/S (NVO) seeing stock prices soar. These medications are reshaping a health care market that serves the 40% of U.

Australia's agriculture sector is poised for a strong year, but the Trump presidency, global conflicts and anti-obesity medications are creating uncertainty.

Ozempic and other semaglutide medications have skyrocketed in popularity as weight-loss aids, with prescriptions surging by over 300% in the past year alone. Developed as a treatment for managing Type 2 diabetes,